Glucose-insulin-potassium and reperfusion in acute myocardial infarction: Rationale and design of the Glucose-Insulin-Potassium Study-2 (GIPS-2)

If high-dose GIK significantly reduces mortality at 30 days in all patients, the adjunction of this treatment to reperfusion therapy may become part of standard regimen for patients with acute MI without heart failure.